PTSD Special Report, Part II: Promising Treatments and Emerging Opportunities
This is Part II of our special report on PTSD, a survey of the rising causes for concern and potential treatments to combat it.
Featured Articles
Advaxis Receives Best Therapeutic Vaccine Award
The 5th Annual Vaccine Industry Excellence Awards has named Advaxis as the Best Therapeutic Vaccine for the company’s ADVX-HPV construct.
PTSD Special Report: Part I, How to Curb a Potential Epidemic
In response to a recent press release from TONIX Pharmaceuticals, a leading company in the exploration of alternative PTSD treatment, we are issuing a 2-part special report looking at recent developments
Dr. Cynthia Haines, Health Information Guru: How Patients Can Combat a Broken Healthcare System
In this unprecedented age of technology and communication, many wonder why the healthcare industry has traditionally not been on the cutting edge.
Brain Resource: Revolutionizing a Common Perception of Depression
Their concept is simple: positive thoughts reduce depression. Train your brain to increase positive thoughts.
JOBS Act Summary: The Reed Smith Bulletin
Reed Smith LLP, a global business law firm, recently issued a JOBS Act bulletin to its network. The bulletin, co-authored by seven partners on both coasts, summarizes and analyzes the JOBS Act.
Patent Infringement Special Report: Part III, the Future of Drug Development
Part Three of our Special Report analyzes what may be one of the first ‘test cases’ of the new patent infringement precedent.
Patent Infringement Special Report: Part II, History and Precedent
Part two of our Special Report highlight an important case that may significantly affect the patent infringement landscape. Shares of Myriad Genetics fell 10 percent in the wake of the Mayo ruling.
PLC Announces Approval to Distribute RenalGuard® in Brazil
“Approval to sell RenalGuard in Brazil is yet another significant development for PLC,” said Mark R. Tauscher, President and Chief Executive Officer of PLC Systems.
ALS TDI -The First Non Profit Biotech, A Hidden Investment Opportunity?
Strategically, the organization has done a good job in moving drugs through clinical trials but lacks venture capital funding. But the benefit investors stand to gain is a major stakehold in the drug with a low investment.